SCHEMBL3391165

SCHEMBL3391165

NNc1ccc(Sc2ccc3ccccc3n2)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSD P07339 1/20 0.49
HPGD P15428 3/20 0.40
HTT P42858 1/20 0.40
LMNA P02545 3/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
PRNP P04156 5/20 0.40
RXFP1 Q9HBX9 4/20 0.40
KDM4E B2RXH2 2/20 0.40
RAB9A P51151 2/20 0.40
NPC1 O15118 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
NCF1 P14598 2/20 0.39
NOS2 P35228 1/20 0.39
BACE1 P56817 1/20 0.39
ALDH1A1 P00352 6/20 0.38
MAPT P10636 4/20 0.38
GAA P10253 2/20 0.38
NPSR1 Q6W5P4 3/20 0.38
MAPK10 P53779 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3389504 0.81 KDM1A (0.53) CTSDHPGDHTTLMNAMEN1
SCHEMBL29980222 0.81 HPGD (0.58) CTSDHPGDHTTPRNPRXFP1
SCHEMBL2114821 0.81 HPGD (0.58) CTSDHPGDHTTPRNPRXFP1
SCHEMBL31280487 0.78 SMN1; SMN2 (0.63) CTSDHPGDHTTMEN1KMT2A
SCHEMBL8737022 0.78 SMN1; SMN2 (0.63) CTSDHPGDHTTMEN1KMT2A
Ammonia Solution, Strong SCHEMBL28220200 0.78 HPGD (0.55) CTSDHPGDHTTLMNAPRNP
SCHEMBL6899659 0.76 RXFP1 (0.53) HPGDLMNAMEN1KMT2APRNP
Ammonia Solution, Strong SCHEMBL28220927 0.75 SMN1; SMN2 (0.59) CTSDHPGDHTTMEN1KMT2A
SCHEMBL8565804 0.75 HPGD (0.43) CTSDHPGDHTTLMNAMEN1
SCHEMBL2098479 0.72 RXFP1 (0.53) HPGDLMNAMEN1KMT2APRNP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100298343-A1 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS AMIRA PHARMACEUTICALS, INC. 2010-11-25 US disclosed
US-20100298343-A1 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS AMIRA PHARMACEUTICALS, INC. 2010-11-25 US disclosed
US-20100298343-A1 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS AMIRA PHARMACEUTICALS, INC. 2010-11-25 US disclosed
EP-2207547-A2 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS Amira Pharmaceuticals, Inc. (US) 2010-07-21 EP disclosed
WO-2009045700-A2 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS AMIRA PHARMACEUTICALS, INC. (US) 2009-04-09 WO disclosed
WO-2009045700-A2 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS AMIRA PHARMACEUTICALS, INC. (US) 2009-04-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298343-A1 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS ALOX5, ALOX15B, ALOX15 CTSD 1552/4885HPGD 81/4885HTT 4772/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.